Caribou Biosciences logo

Caribou BiosciencesNASDAQ: CRBU

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

23 July 2021

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$201.51 M
-85%vs. 3y high
53%vs. sector
-vs. 3y high
-vs. sector
-81%vs. 3y high
33%vs. sector
-96%vs. 3y high
65%vs. sector

Price

after hours | Fri, 01 Nov 2024 22:02:05 GMT
$2.23+$0.27(+13.78%)

Dividend

No data over the past 3 years
$3.46 M$3.10 M
$3.46 M-$37.70 M

Analysts recommendations

Institutional Ownership

CRBU Latest News

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
seekingalpha.com30 September 2024 Sentiment: POSITIVE

Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform offers precise genome editing and could potentially outperform competitors like Allogene Therapeutics. CRBU's flagship candidate, CB-010, shows promising results in Phase 1 trials for large B cell lymphoma, with long-term complete response rates.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
accesswire.com19 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ:CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
prnewswire.com17 August 2024 Sentiment: NEGATIVE

NEW YORK , Aug. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
globenewswire.com12 August 2024 Sentiment: POSITIVE

-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clinical programs for hematologic malignancies and autoimmune diseases. Dr. Albertson will report to Rachel Haurwitz, PhD, Caribou's president and chief executive officer.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
prnewswire.com09 August 2024 Sentiment: NEGATIVE

NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
accesswire.com07 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ:CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.48 per share a year ago.

Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
zacks.com06 August 2024 Sentiment: NEGATIVE

Caribou Biosciences (CRBU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
globenewswire.com03 August 2024 Sentiment: NEGATIVE

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU).   Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
prnewswire.com01 August 2024 Sentiment: NEGATIVE

NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

  • 1(current)
  • 2
  • 3

What type of business is Caribou Biosciences?

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

What sector is Caribou Biosciences in?

Caribou Biosciences is in the Healthcare sector

What industry is Caribou Biosciences in?

Caribou Biosciences is in the Biotechnology industry

What country is Caribou Biosciences from?

Caribou Biosciences is headquartered in United States

When did Caribou Biosciences go public?

Caribou Biosciences initial public offering (IPO) was on 23 July 2021

What is Caribou Biosciences website?

https://cariboubio.com

Is Caribou Biosciences in the S&P 500?

No, Caribou Biosciences is not included in the S&P 500 index

Is Caribou Biosciences in the NASDAQ 100?

No, Caribou Biosciences is not included in the NASDAQ 100 index

Is Caribou Biosciences in the Dow Jones?

No, Caribou Biosciences is not included in the Dow Jones index

When was Caribou Biosciences the previous earnings report?

No data

When does Caribou Biosciences earnings report?

The next expected earnings date for Caribou Biosciences is 07 November 2024